ASH 2022 Leukemia Highlights

CME

Key Studies in Leukemias: Independent Conference Coverage of ASH 2022

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 21, 2023

Expiration: March 20, 2024

Amir T. Fathi
Amir T. Fathi, MD
Eunice S. Wang
Eunice S. Wang, MD

Activity

Progress
1
Course Completed
References

  1. Lagadinou E, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329-341. 
  2. DiNardo C, Jonas B, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617-629.
  3. Venetoclax [prescribing information]. North Chicago, IL and South San Francisco, CA: AbbVie and Genentech USA; 2022.
  4. Pratz KW Jonas B, Pullarkat V, et al. Long-term follow-up of the phase 3 VIALE-A clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 219.
  5. Willekens C, Chraibi S, Decroocq J, et al. Reduced venetoclax exposition to seven days of azacitidine is efficient in treatment-naive patients with acute myeloid leukemia. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 222.
  6. Daver N, Senapati J, Maiti A, et al. Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 61.
  7. Sallman D, Asch A, Kambhampati S, et al. The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: phase 1b results. Clin Lymph Myeloma Leukemia. 2021;21:S290. 
  8. Sallman D, Asch A, Kambhampati S, et al. The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: phase 1b results. Presented at: 2020 American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 330.
  9. Fiskus W, Daver N, Boettcher S, et al. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia. 2022;36:2729-2733.
  10. Erba H, Fathi A, Issa G, et al. Update on a phase 1/2 first-in-human study of the menin-KMT2A (MLL) inhibitor ziftomenib (KO-539) in patients with relapsed or refractory acute myeloid leukemia. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 64.
  11. Swaminathan M, Bourgeois W, Armstrong SA, et al. Menin inhibitors in acute myeloid leukemia—what does the future hold? Cancer J. 2022;28:62-66.
  12. Short N, DiNardo CD, Daver N, et al. Updated results from a phase I/II study of the triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 831.
  13. Konopleva M, Thirman MG, Pratz KW, et al. Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naive acute myeloid leukemia. Clin Cancer Res. 2022;28:2744-2752.
  14. Wang E, Montesinos P, Minden M, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140:1845-1857.
  15. McCloskey J, Pullarkat VA, Mannis GN, et al. V-FAST master trial: subgroup analysis of outcomes with CPX-351 plus midostaurin in adults with newly diagnosed acute myeloid leukemia by FLT3 mutation type. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 1436.
  16. Litzow MR, Sun Z, Paietta E, et al. Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized phase III National Cooperative Clinical Trials Network Trial. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract LBA1.
  17. Boissel N, Huguet F, Leguay T, et al. Blinatumomab during consolidation in high-risk Philadelphia Chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) adult patients: a two-cohort comparison within the GRAALL-2014/B study. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 211.
  18. Stelljes M, Alakel N, Wasch R, et al. Inotuzumab ozogamicin induction followed by standard chemotherapy yields high remission rates and promising survival in older (>55 years) patients with de novo B-lymphoblastic leukemia (GMALL-INITIAL1 Trial). Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 212.
  19. Khongorzul P, Ling CJ, Khan UF, et al. Antibody–drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18:3-19.
  20. Réa D, Mauro M, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031-2041.
  21. Cortes J, Hughes T, Geissler J, et al. Efficacy and safety results from ASC4MORE, a randomized study of asciminib (ASC) add-on to imatinib (IMA), continued IMA, or switch to nilotinib (NIL) in patients (Pts) with chronic-phase chronic myeloid leukemia (CML-CP) not achieving deep molecular responses (DMRs) with ≥1 year of IMA. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 80.
  22. Dasatinib [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2023.
  23. Naqvi K, Jabbour E, Skinner J, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020;127:67-75.
  24. Gener-Ricos G, Haddad F, Sasaki K, et al. Long-term follow-up of low-dose dasatinib (50mg daily) as frontline therapy in newly diagnosed chronic myeloid leukemia. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 619.